Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa học: "Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. | Critical Care April 2004 Vol 8 No 2 Kinasewitz et al. Research Open Access Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis regardless of causative micro-organism ISRCTN74215569 Gary T Kinasewitz1 S Betty Yan2 Bruce Basson2 Philip Comp1 James A Russell3 Alain Cariou4 Suzane L Um2 Barbara Utterback2 Pierre-Francois Laterre5 and Jean-Franọois Dhainaut4 for the PROWESS Sepsis Study Group 1 Department of Medicine Physiology and Biophysics University of Oklahoma Health Science Center and Cardiovascular Biology Oklahoma Medical Research Foundation Oklahoma City Oklahoma USA 2Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana USA 3St Paul s Hospital Vancouver British Columbia Canada 4Service de Réanimation Médicale Centre Hospitalo-Universitaire Cochin Port-Royal AP-HP Paris V University Paris France 5Cliniques Universitares St. Luc Brussels Belgium Correspondence S Betty Yan Yan_Sau_Chi_Betty@Lilly.com Received 16 December 2003 Revisions requested 22 December 2003 Accepted 14 January 2004 Published 10 February 2004 Critical Care 2004 8 R82-R90 DOI 10.1186 cc2459 This article is online at http ccforum.com content 8 2 R82 2004 Kinasewitz et al. licensee BioMed Central Ltd Print ISSN 1364-8535 Online ISSN 1466-609X . This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Introduction PROWESS Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis was a phase III randomized double blind placebo controlled multicenter trial conducted in patients with severe sepsis from 164 medical centers. Here we report data collected at study entry for 1690 patients and over the following 7 days for the 840 patients who received placebo in addition to usual standard of care . Methods Nineteen biomarkers of coagulation activation anticoagulation .